logo
The EU-U.S. trade deal could have one unexpected winner: The UK

The EU-U.S. trade deal could have one unexpected winner: The UK

CNBC7 days ago
As world leaders and economists across Europe digest the news of the EU-U.S. trade agreement, some experts told CNBC that while it may be bad news for the bloc, the deal could serve as an unexpected boost to the U.K.
The European Union is facing a higher 15% tariff rate on its goods imported to the U.S. compared to the 10% levy the U.K. has agreed to.
"In theory, the UK benefits," Philip Shaw, chief economist at Investec, told CNBC.
"The new EU tariff of 15% means that UK exports to the US have become relatively cheaper, which could boost British trade with the US as American firms buy goods from Britain rather than the EU," he explained.
U.K. goods would also be cheaper for U.S. consumers due to the lower tariff rate, meaning they may favor British products over those manufactured in the EU, Alex Altmann, partner and head of Lubbock Fine LLP's German desk, suggested in a note published shortly after the EU-U.S. deal was announced.
"The UK's lower US tariffs do offer a major incentive for EU companies to shift some of their manufacturing bases to the UK or to expand their existing UK facilities," he added.
EU-based manufacturers with low profit margins in particular could find the idea of moving to the U.K. attractive to avoid a further squeeze on those margins, Altmann explained, noting that the U.K. has spare manufacturing capacity due to Brexit.
"The UK could be a big indirect winner of this agreement," Altmann added.
But the benefits to the U.K. are not only linked to the country's lower tariff rate. Indeed, the EU managing to secure a 15% levy, which is far lower compared to the 30% the bloc was threatened with by U.S. President Donald Trump, could also be a positive for the U.K. according to Investec's Shaw.
"The EU has escaped from a possible major downturn from a more onerous (i.e. 30%) tariff regime and possibly a series of retaliatory measures between the two trading blocs. Here the UK benefits from its major trading partner averting a recession which could have resulted in a decline in UK exports to the EU," he said in written comments.
The EU-U.S. reaching an agreement has also hampered the potential impact, Beth McCall, an international trade lawyer at Dentons told CNBC.
"If the US had proceeded with 30% tariffs against most EU goods, UK goods with a 10% tariff, which is paid by the US importer in most circumstances, could have appeared significantly more attractive," she said.
McCall noted that the expected difference in the baseline tariff rate, which amounts to just 5%, may still make some U.K. goods more attractive. However, she noted, "this will take time to be seen as existing contracts come to an end and US importers search for imports from countries carrying a lower tariff."
Questions have been raised about the timeframe for the impact of tariffs being felt around the world has been a frequently debated question. Companies have already flagged that tariffs are expected to weigh on their earnings, and there have been widespread warnings of how the duties could impact economic growth.
But as many details of the trade agreements have yet to be ironed out, their precise exact impact is still unclear. Some of the effects may also take time to be felt, for example rising costs for consumers may only materialize after some time.
Ultimately, both the U.K. and EU are now facing a more difficult environment, McCall said.
"Whether the new rate is 10% or 15%, UK and EU businesses will still face far higher tariffs when exporting to the US than they did three months ago," she said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Shake Shack CEO says 'productivity' helps mitigate inflated beef costs
Shake Shack CEO says 'productivity' helps mitigate inflated beef costs

CNBC

time25 minutes ago

  • CNBC

Shake Shack CEO says 'productivity' helps mitigate inflated beef costs

Shake Shack CEO Rob Lynch reviewed his company's most recent quarter in a Monday interview with CNBC's Jim Cramer, and he described how the burger chain manages to mitigate the inflated cost of ingredients like beef without steep price hikes. "We've built so much productivity over the last year, our operating margins have gone from right around 20 up to 24%, almost 24% last quarter," he said. "We're right now working within our supply chain to find a lot more productivity, so we're able to mitigate that inflation with all the productivity." Even as Shake Shack beat revenue and earnings estimates when it reported last week, shares declined as investors worried about a lower-than-expected same-store sales figure. The stock is currently down a little over 11% year-to-date. According to Lynch, Shake Shack no longer depends on pricing to drive growth and now sees traffic as a significant driver of "healthy, sustainable growth." He said Shake Shack is "never going to be the lowest price point product out there," as its products cost more to make. Lynch said the company is looking at other ways to provide customers with value, such as a $1 drink promotion on its app. He also mentioned newer offerings, like alcoholic beverages — "boozy shakes, classic cocktails, full bar" — at certain locations. Lynch maintained that Shake Shack has pricing power if inflation skyrockets. "I mean, we still have pricing power, if we choose, if we need to, if there's enough inflation," he said. "So pricing will always be a part of the model, but it's, we're not dependent upon it like we used to be." Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest

Palantir smashes expectations with $1 billion Q2 revenue as CEO boasts that skeptics have been 'bent into a kind of submission'
Palantir smashes expectations with $1 billion Q2 revenue as CEO boasts that skeptics have been 'bent into a kind of submission'

Business Insider

time25 minutes ago

  • Business Insider

Palantir smashes expectations with $1 billion Q2 revenue as CEO boasts that skeptics have been 'bent into a kind of submission'

Palantir's CEO, Alex Karp, saw no reason to be humble after his company's blockbuster second-quarter earnings. "As usual, I've been cautioned to be a little modest about our bombastic numbers, but there's no authentic way to be anything but have enormous pride and gratefulness about these extraordinary numbers," he said as he kicked off his part of the earnings call on Monday. He struck a similar tone in his letter to shareholders. "The skeptics are admittedly fewer now, having been defanged and bent into a kind of submission," he wrote. The Denver-based AI software company beat analyst estimates Monday with adjusted earnings of 16 cents per share on $1 billion in revenue, topping LSEG projections of 14 cents and $940 million, respectively. The stock peaked at more than 5% in after-hours trading compared to when the market closed at 4 p.m ET. Palantir 's commercial revenue in the US nearly doubled since last year's second quarter to $628 million, while government revenue climbed 53% year-over-year to $426 million, mostly thanks to a 10-year, $10 billion contract with the US Army, which consolidated 75 contracts into one. Ryan Taylor, chief revenue officer and chief legal officer, said that the US Space Force awarded the company a $218 million delivery order and raised the spending ceiling for Palantir's Maven Smart System to $795 million in preparation for "significant demand." The company also raised its full-year revenue guidance midpoint to just north of $4 billion, a nine-point increase from last quarter. Karp concluded the call with a message for investors. "Maybe stop talking to all the haters — they're suffering," he said.

Why Curaleaf Stock Popped by 15% on Monday
Why Curaleaf Stock Popped by 15% on Monday

Yahoo

time41 minutes ago

  • Yahoo

Why Curaleaf Stock Popped by 15% on Monday

Key Points Good news benefiting the cannabis industry was beneficial for the company too. There were pot-positive developments on both the medical and political fronts. 10 stocks we like better than Curaleaf › Pardon the use of the adjective, but it was obvious on Monday that the market has high hopes for cannabis company Curaleaf (OTC: CURLF). Investors piled into the stock after some positive news developments affecting its industry hit the headlines. By the time the smoke had cleared, Curaleaf was left standing with a more than 15% gain in its stock price that day. This obliterated the 1.4% advance of the S&P 500 index. Drug of choice The first news item producing that buzz was research published by the influential American Medical Association (AMA). In its Journal of the American Medical Association, the AMA detailed research from a survey that evaluated a clutch of drugs for how they affected eating disorders. Of the numerous drugs tested, the Journal noted, cannabis and psychedelic compounds were the highest-rated for alleviating symptoms of eating disorders. On top of that, marijuana and the psychedelics LSD and psilocybin also performed well in terms of overall mental health. These contrasted with the generally weak showing of nicotine and alcohol, which the Journal said were frequently ranked by the respondents as being the most harmful substances. Marijuana is legally sold as a medicine to qualifying patients in most U.S. states. If the drug can indeed treat eating disorders, this could dramatically enhance its appeal as a medical drug. Pot lobbying Another item of interest was Federal Election Commission (FEC) filings cited by several media outlets revealing that a pot industry-supported political action committee (PAC) made a meaty donation to President Trump's MAGA Inc. This is a so-called "super PAC" entitled to raise unlimited amounts of money to support political figures. The American Rights and Reform PAC, fueled by donations from marijuana companies, has donated $1 million to MAGA Inc. Although that's relatively small given the over $177 million the latter absorbed in the first six months of the year, this does indicate that the weed industry is actively lobbying influential people in U.S. politics. Should you buy stock in Curaleaf right now? Before you buy stock in Curaleaf, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Curaleaf wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Curaleaf Stock Popped by 15% on Monday was originally published by The Motley Fool Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store